MedTrace Logo

Galectin-3 in Septic and Non-septic Acute Kidney Injury

NCT05691621 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2023-01-20

No results posted yet for this study

Summary

Acute kidney injury (AKI) is a common critical condition with high morbidity and mortality. The level of circulating Galectin-3 (Gal3) largely depends on renal function, so it is elevated in patients with AKI or CKD; elevated Gal3 also aggravates the progression of CKD after the onset of AKI. The proinflammatory and profibrotic properties of Gal3 may render it to be one of the key molecules mediating AKI, CKD, and cardiorenal syndrome. In this prospective observational study, the investigators will explore the differences of Gal3 levels among septic AKI, non-septic AKI, and non-AKI patients and its correlation with prognosis, inflammation, and disease severity in the ICU.

Conditions

Interventions

DRUG

Standard Reagents, Whole Blood

All patients receive standard treatment, only their blood and urine samples are needed

Sponsors & Collaborators

  • Wuhan University

    collaborator OTHER

  • Fengyun Wang

    lead OTHER

Principal Investigators

  • Fengyun Wang, Doctor · First People's Hospital of Foshan

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-08-31
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05691621 on ClinicalTrials.gov